Cinacalcet hydrochloride and Hyperparathyroidism tertiary - a phase IV clinical study of FDA data

Summary:

Hyperparathyroidism tertiary is reported as a side effect among people who take Cinacalcet hydrochloride (cinacalcet hydrochloride), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Calcium Carbonate, and have Hyperparathyroidism secondary.

The phase IV clinical study analyzes which people have Hyperparathyroidism tertiary when taking Cinacalcet hydrochloride. It is created by eHealthMe based on reports of 2,315 people who have side effects when taking Cinacalcet hydrochloride from the FDA, and is updated regularly.

What is Cinacalcet hydrochloride?

Cinacalcet hydrochloride has active ingredients of cinacalcet hydrochloride. eHealthMe is studying from 2,334 Cinacalcet hydrochloride users. Check the latest studies of Cinacalcet hydrochloride.

What is Hyperparathyroidism tertiary?

Hyperparathyroidism tertiary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-tertiary) is found to be associated with 9 drugs and 30 conditions by eHealthMe. Check the latest studies of Hyperparathyroidism tertiary.

On Jul, 27, 2026

2,315 people reported to have side effects when taking Cinacalcet hydrochloride.
Among them, 14 people (0.6%) have Hyperparathyroidism tertiary.

Could Cinacalcet hydrochloride cause Hyperparathyroidism tertiary?

Among these 14 people:

How long have people been on Cinacalcet hydrochloride when they have Hyperparathyroidism tertiary? *

What is the gender of people who have Hyperparathyroidism tertiary when taking Cinacalcet hydrochloride? *

female: 58.33 %
male: 41.67 %

What is the age of people who have Hyperparathyroidism tertiary when taking Cinacalcet hydrochloride? *

What are other drugs people take besides Cinacalcet hydrochloride? *

Zemplar: 2 people, 14.29%
Vitamin D: 2 people, 14.29%
Renagel: 2 people, 14.29%
Pregabalin: 2 people, 14.29%
Calcium Carbonate: 2 people, 14.29%
Zoledronic Acid: 1 person, 7.14%
Tacrolimus: 1 person, 7.14%
Sevelamer Hydrochloride: 1 person, 7.14%
Risedronate Sodium: 1 person, 7.14%
Folic Acid: 1 person, 7.14%

What are other side effects people have besides Hyperparathyroidism tertiary? *

Hypocalcaemia (levels of calcium in blood serum are abnormally low): 2 people, 14.29%
Kidney Stones: 2 people, 14.29%
Blood Parathyroid Hormone Increased: 2 people, 14.29%
Peripheral Arterial Occlusive Disease (reproducible ischemic muscle pain): 2 people, 14.29%
Hypercalcaemia (elevated calcium (ca+) level in the blood): 2 people, 14.29%
Diarrhea: 2 people, 14.29%
Death: 1 person, 7.14%
Heart Disease: 1 person, 7.14%
Haematoma (collection of blood outside the blood vessels): 1 person, 7.14%
Drug Ineffective: 1 person, 7.14%

What are the existing conditions these people have? *

Hyperparathyroidism Secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary): 8 people, 57.14%
Pain: 2 people, 14.29%
Hyperparathyroidism (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium): 2 people, 14.29%
Anaemia (lack of blood): 2 people, 14.29%
Rickets (softening of bones): 1 person, 7.14%
Osteoporosis (bones weak and more likely to break): 1 person, 7.14%
Immunodeficiency Disorders: 1 person, 7.14%
Hypercalcaemia (elevated calcium (ca+) level in the blood): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Cinacalcet hydrochloride and have Hyperparathyroidism tertiary?

- Check whether Hyperparathyroidism tertiary is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cinacalcet hydrochloride:

Cinacalcet hydrochloride (2,334 reports)

Browse all side effects of Cinacalcet hydrochloride:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hyperparathyroidism tertiary:

Hyperparathyroidism tertiary (9 drugs)

Browse all the conditions that are associated with Hyperparathyroidism tertiary:

Hyperparathyroidism tertiary (30 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on cinacalcet hydrochloride (the active ingredients of Cinacalcet hydrochloride) and Cinacalcet hydrochloride (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.